Marvell Technology Inc vs Zoetis Inc — how do they compare? Marvell Technology Inc trades at $275.28 (market cap $246.84B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Marvell Technology Inc is far larger — about 8.2× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Zoetis Inc for 70 Days on average.
| MRVL | ZTS | |
|---|---|---|
Market Cap | $246.84B | $30.20B |
Volume | 29,003,830 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $316.43 | $147.53 |
52-Week Low | $73.73 | $69.09 |
Typical Hold Time | 42 Days | 70 Days |
Enterprise Value | $248.19B | $37.76B |
Dividend Yield | 0.09% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day but maintains strong technical momentum with bullish moving averages and key support at $267. The company shows impressive earnings beats in recent quarters with Q2 2026 EPS of $0.94 beating expectations, while analyst consensus remains overwhelmingly bullish with 84% buy ratings. Recent news highlights Marvell's AI chip growth potential, including a major Google partnership and raised 2028 revenue guidance to $18 billion.
Marvell presents compelling growth prospects driven by AI infrastructure demand and custom chip expansion, though elevated valuation ratios (P/E 90.95, P/S 25.77) warrant caution. Key risks include execution challenges in scaling custom silicon business and competitive pressures in the semiconductor sector. The $327.86 consensus price target suggests 19% upside potential from current levels.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →